Drug Profile


Alternative Names: r-hTBP; r-hTBP-1; r-TBP-1; TBP; TBP 1; TBP I; TNF-BP1; Tumour necrosis factor antagonist; Tumour necrosis factor binding protein 1

Latest Information Update: 07 Apr 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Weizmann Institute of Science
  • Developer Yeda
  • Class Anti-inflammatories; Antirheumatics; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Crohn's disease; Endometriosis; Psoriasis; Psoriatic arthritis; Reperfusion injury; Rheumatoid arthritis; Septic shock

Most Recent Events

  • 05 Jan 2007 Serono has been acquired by Merck KGaA
  • 06 Sep 2005 Discontinued - Phase-II for Crohn's disease in Canada (Parenteral)
  • 06 Sep 2005 Discontinued - Phase-II for Crohn's disease in Italy (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top